It is clear that we need a viable, strong, active and even interventionist FDA. But we also need new antibiotics. How did we get to a place where these two obvious needs might be in conflict?
KeywordsAdvisory Committee Clinical Trial Design Infectious Disease Society Infectious Disease Physician Acute Bacterial Sinusitis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
© Springer Science+Business Media B.V. 2010